Teva Appeals Ruling Forcing It to Cede Inhaler Patent Protection

A Teva Pharmaceutical Industries Ltd. unit asked the Federal Circuit to overturn a ruling that would allow a generic drug maker to introduce a competitor to Teva’s ProAir HFA inhaler.

The lower court decision, if undisturbed, would require Teva to de-list five patents related to the company’s inhaler, used to treat asthma and various other lung diseases, from the US Food and Drug Administration’s Orange Book, an agency list of patents that protect name-brand drugs from generic competition. The June ruling came in response to legal efforts by Amneal Pharmaceuticals of New York LLC and its affiliates, which sought ...